Eli Lilly's shares have dipped 11% since June, but Millennium Management increased its stake by 86% in the third quarter. Despite recent setbacks, Lilly's strong pipeline and potential blockbuster medicines suggest long-term growth. Investors should consider its promising future beyond short-term fluctuations.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing